Antengene Corp. Ltd. and Antengene Discovery Ltd. have divulged phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors acting as ferroptosis inducers reported to be useful for the treatment of cancer.
Scientists at Unity Health Toronto and University of British Columbia have identified aeroplysinin derivatives reported to be useful for the treatment of asthma, atherosclerosis, autoimmune disease, diabetic nephropathy and more.
Jiangsu Synthgene Biotechnology Co. Ltd. has synthesized platinum complexes acting as radiosensitizers reported to be useful for the treatment of cancer.
Voronoi Inc. has disclosed heteroaryl compounds acting as Myt1 kinase (PKMYT1) and/or Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a modulator of IL-1 receptor and Toll-like receptor (TLR) signaling and has emerged as a promising therapeutic target for several inflammatory diseases. Gilead Sciences Inc. and Nurix Therapeutics Inc. recently presented data generated in a preclinical murine model of AD with their IRAK-4 degrader GS-6791.
In heart failure, the heart does not oxygenate body tissues adequately. A standard treatment is SGLT2 inhibitors such as empagliflozin and dapagliflozin, derived from the national product phlorizin. However, long-term use of these inhibitors increases risk of renal damage and euglycemic diabetic ketoacidosis.
Chineses researchers investigated the relationship between formyl peptide receptor 1 (FPR1) expression and neurodegeneration in multiple sclerosis (MS), specifically evaluating the therapeutic potential of the FPR1 antagonist T-0080.
Biolinerx Ltd. and Hemispherian AS have established a joint venture (JV) to develop GLIX-1, Hemispherian’s lead drug candidate being developed as a potential treatment for newly diagnosed and recurrent glioblastoma.
Climb Bio Inc. has announced results from a completed nonhuman primate (NHP) study of CLYM-116, an anti-APRIL monoclonal antibody (mAb) in development for IgA nephropathy.
RSS
